tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ABOS Stock Latest News

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
Press ReleasesAcumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
16d ago
ABOS
Acumen Pharmaceuticals Unveils Updated Corporate Presentation and Financials
PremiumCompany Announcements
Acumen Pharmaceuticals Unveils Updated Corporate Presentation and Financials
1M ago
8K
ABOS
Acumen reports Q2 EPS (34c), consensus (28c)
PremiumThe Fly
Acumen reports Q2 EPS (34c), consensus (28c)
1M ago
ABOS
Acumen Pharmaceuticals, Inc. (ABOS) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Acumen Pharmaceuticals, Inc. (ABOS) Q2 Earnings Cheat Sheet
1M ago
ABOS
Acumen announces first subject dosed in Phase 1 study of sabirnetug
PremiumThe Fly
Acumen announces first subject dosed in Phase 1 study of sabirnetug
2M ago
ABOS
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
PremiumPress ReleasesAcumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
2M ago
ABOS
Acumen presents patient experience, biomarker Data from Phase 1 INTERCEPT-AD
Premium
The Fly
Acumen presents patient experience, biomarker Data from Phase 1 INTERCEPT-AD
2M ago
ABOS
Acumen initiated with a Buy at Citi
Premium
The Fly
Acumen initiated with a Buy at Citi
2M ago
ABOS
Acumen will present patient experience, data from Phase 1 INTERCEPT-AD study
PremiumThe Fly
Acumen will present patient experience, data from Phase 1 INTERCEPT-AD study
2M ago
ABOS
Acumen Pharmaceuticals Begins Phase 2 Trial and Updates Finances
PremiumCompany Announcements
Acumen Pharmaceuticals Begins Phase 2 Trial and Updates Finances
4M ago
8K
ABOS
Acumen sees cash runway into 1H27
PremiumThe Fly
Acumen sees cash runway into 1H27
4M ago
ABOS
Acumen reports Q1 EPS (25c), consensus (26c)
PremiumThe Fly
Acumen reports Q1 EPS (25c), consensus (26c)
4M ago
ABOS
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
PremiumPress ReleasesAcumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
4M ago
ABOS
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
Premium
Press Releases
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
4M ago
ABOS
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
Premium
Press Releases
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
4M ago
ABOS
Acumen announces first patient dosed in ALTITUDE-AD study
PremiumThe Fly
Acumen announces first patient dosed in ALTITUDE-AD study
4M ago
ABOS
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
PremiumPress Releases
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
5M ago
ABOS
These 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analysts
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analysts
5M ago
ABOS
ELDN
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
PremiumPress Releases
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
5M ago
ABOS
Acumen presents first clinical, biomarker data for ACU193
PremiumThe FlyAcumen presents first clinical, biomarker data for ACU193
5M ago
ABOS
Acumen teams with Lonza for advancement of sabirnetug to treat AD
Premium
The Fly
Acumen teams with Lonza for advancement of sabirnetug to treat AD
6M ago
ABOS
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Premium
Press Releases
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
6M ago
ABOS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >